Elevated AKAP12 in Paclitaxel-Resistant Serous Ovarian Cancer Cells Is Prognostic and Predictive of Poor Survival in Patients

Author:

Bateman Nicholas W.1,Jaworski Elizabeth1,Ao Wei1,Wang Guisong1,Litzi Tracy1,Dubil Elizabeth12,Marcus Charlotte12,Conrads Kelly A.1,Teng Pang-ning1,Hood Brian L.1,Phippen Neil T.12,Vasicek Lisa A.1,McGuire William P.3,Paz Keren4,Sidransky David5,Hamilton Chad A.12,Maxwell G. Larry16,Darcy Kathleen M.1,Conrads Thomas P.1

Affiliation:

1. Women’s Health Integrated Research Center at Inova Health System, Gynecologic Cancer Center of Excellence, 3289 Woodburn Road, Annandale, Virginia 22003, United States

2. Gynecologic Oncology Service, Department of Obstetrics and Gynecology, Walter Reed National Military Medical Center, 8901 Wisconsin Avenue, Bethesda, Maryland 20814, United States

3. Massey Cancer Center, Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia 23298, United States

4. Champions Oncology, Inc., 855 North Wolfe Street, Suite 619, Baltimore, Maryland 21205, United States

5. Otolaryngology−Head and Neck Surgery and Oncology, Johns Hopkins University, 1550 Orleans Street, Baltimore, Maryland 21287, United States

6. Department of Obstetrics and Gynecology, Inova Fairfax Hospital, 3300 Gallows Road, Falls Church, Virginia 22042, United States

Funder

Medical Research and Materiel Command, U.S. Army Medical Department

Publisher

American Chemical Society (ACS)

Subject

General Chemistry,Biochemistry

Reference51 articles.

1. A Snapshot of Ovarian Cancer;National Cancer Institute:Bethesda, MD, 2013.

2. Statistics;Ovarian Cancer National Alliance:Washington, DC;http://www.ovariancancer.org/about/statistics/.

3. SEER Cancer Statistics Factsheets: Ovary Cancer;National Cancer Institute:Bethesda, MD;http://seer.cancer.gov/statfacts/html/ovary.html.

4. Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer

5. Ovarian cancer: strategies for overcoming resistance to chemotherapy

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3